Study guide
10.8 Literature Evaluation: Research Methods, Statistics & Stability Evidence
BCSCP Board Certified Sterile Compounding Pharmacist Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Overview, USP Standards & CSP Categories
1.1 BCSCP Exam Format, Eligibility, Scoring & 2024 Content Outline 1.2 USP <797> Scope, Core Philosophy & Regulatory Framework 1.3 USP <797> Categories 1, 2, and 3 CSP Classification 1.4 Immediate-Use CSPs: The 4-Hour Rule and Its Conditions
2 Chapter 2: Facilities, Engineering Controls & Cleaning
2.1 Cleanroom Architecture & ISO Classifications 2.2 Primary Engineering Controls (PECs) & Laminar Airflow Dynamics 2.3 Segregated Compounding Areas (SCAs) & Containment SCAs (C-SCAs) 2.4 HVAC Engineering Controls, Pressure Differentials & Air Exchange 2.5 Equipment & Materials in Classified Areas Under Dynamic Conditions 2.6 Cleaning, Disinfecting, Sporicidal Agents & Sterile 70% IPA 2.7 Contingency Planning: Power, HVAC, Supply and Staffing Failures
3 Chapter 3: Environmental Monitoring & Facility Certification
3.1 Viable Airborne Microbial Monitoring 3.2 Total Airborne Non-Viable Particle Counting & Cleanroom Certification Standards 3.3 Surface Microbial Sampling: Contact Plates, Swabs, Incubation Protocols & Action Levels 3.4 Environmental Sampling Excursions, Trend Analysis, and Remediation Protocols
4 Chapter 4: Hand Hygiene, Garbing & Aseptic Technique
4.1 Hand Hygiene & Cleansing Protocols 4.2 Step-by-Step Garbing Sequence & Ante-Room Logistics 4.3 Direct Compounding Area (DCA) Aseptic Technique & First Air Integrity
5 Chapter 5: Beyond-Use Dating, Storage & Container Rules
5.1 Category 1 Beyond-Use Dating & Storage Limitations 5.2 Category 2 Beyond-Use Dating: Sterile vs. Nonsterile Starting Components 5.3 Category 3 Beyond-Use Dating: Requirements for Extended Dating (60/90/120 Days) 5.4 Container Types, Puncture Limits & Multi-Dose Container Rules
6 Chapter 6: Sterilization, Release Testing & Hazardous Drug Compounding
6.1 Terminal Sterilization vs. Sterilizing Filtration 6.2 Release Testing: Sterility (USP <71>), Endotoxin (USP <85>) & Particulates (USP <788>) 6.3 Container Closure Integrity Testing (CCIT) & Visual Inspection 6.4 USP <800> Hazardous Drug Compounding & Closed System Drug-Transfer Devices (CSTDs)
7 Chapter 7: Materials, Equipment & Compounding Workflow
7.1 Compounding Equipment & Technology: ACDs, Balances, Pumps & IV Workflow Systems 7.2 Compounding Supplies, Containers & Closures 7.3 Component Receipt, Storage & Material Transfer 7.4 Calibration, Verification, Validation & Maintenance of Equipment 7.5 Compounding Workflow: SOPs, Workflow Software, Production Queues & Labeling 7.6 Handling, Storing, Packaging, Transporting & Disposing of Finished CSPs
8 Chapter 8: Calculations, Osmolarity & Physicochemical Compatibility
8.1 Sterile Compounding Calculations: Millimoles, Milliequivalents, Osmolarity & Tonicity Adjustments 8.2 Physical and Chemical Incompatibilities: pH Effects, Salt Formations & Precipitation Mechanisms 8.3 Complex Admixture Compatibility: Calcium-Phosphate Solubility Curves & Parenteral Nutrition Dynamics
9 Chapter 9: Therapeutics, Administration & Patient Monitoring
9.1 Patient-Specific Parameters: Verifying CSP Orders 9.2 Special Administration Routes: Epidural, Intrathecal, Ophthalmic & Intravesical Sterile Preparations 9.3 Medication Delivery Devices, Home Infusion & Patient Education 9.4 High-Alert Sterile Medications, Pediatric/Neonatal Considerations & Extravasation Management 9.5 Therapeutic Drug Monitoring, Catheter-Related Bloodstream Infection (CRBSI) Prevention & Clinical Vigilance 9.6 Medication Adherence in Home and Outpatient Sterile Therapy 9.7 Interprofessional Care Coordination for Sterile Preparations
10 Chapter 10: Quality Management, Records & Personnel Competency
10.1 Master Formulation Records (MFR) vs. Compounding Records (CR) Requirements & Workflow 10.2 Personnel Training, Core Competency & Written Testing Requirements 10.3 Gloved Fingertip and Thumb Sampling (GFT) Testing Cadence, Pass/Fail Thresholds & Action Plans 10.4 Media-Fill Testing Protocols: Simulation Design, Incubation Parameters & Failure Investigations 10.5 Standard Operating Procedures & Document Control 10.6 Quality Assurance & Quality Control Programs 10.7 Inspection Methods, Self-Audits & Continuous Readiness 10.8 Literature Evaluation: Research Methods, Statistics & Stability Evidence
11 Chapter 11: Regulatory Oversight, Accreditation & Drug Supply Chain
11.1 Drug Quality and Security Act (DQSA) & FDA Section 503A Traditional Pharmacies vs. Section 503B Outsourcing Facilities 11.2 State Boards of Pharmacy, FDA Guidance & Inter-Agency Regulatory Jurisdictions 11.3 Drug Supply Chain Security Act (DSCSA), Component Qualification & Certificate of Analysis (CoA) Verification 11.4 CMS, The Joint Commission, CDC, ASPEN & ASHP: Standards Beyond USP and FDA
12 Chapter 12: Safety Management, Investigations, Recalls & Waste
12.1 Root Cause Analysis (RCA), CAPA Framework & Out-of-Specification (OOS) Investigations 12.2 Adverse Drug Event Reporting, FDA MedWatch Form 3500 & Product Recall Protocols 12.3 Occupational Safety, Hazardous Waste Disposal (RCRA / EPA) & Spill Clean-up Management
10.8 Literature Evaluation: Research Methods, Statistics & Stability Evidence
Key Takeaways Explain This Topic AI
Tertiary compatibility and stability references are starting points; for BUD decisions, check the primary study's drug, concentration, diluent, container, temperature and method against the actual CSP.
A stability study can support a BUD only if it uses a validated stability-indicating method, meaning one shown by forced degradation to separate drug from degradants, and tests the same formulation and container materials under the same storage conditions.
Chemical stability is commonly defined as keeping at least 90% of the initial concentration. For first-order degradation, t90 = 0.105 ÷ k.
Physical compatibility studies (visual, Tyndall beam, turbidity, particle counts) apply only to the concentrations and conditions tested. 'Compatible' in one study does not carry over to other conditions.
Clinical studies are judged by design, bias, statistical versus clinical significance, and absolute effect: with an absolute risk reduction (ARR) of 2 percentage points, the number needed to treat (NNT) is 1 ÷ 0.02 = 50.
Last updated: September 2026
10.8 Literature Evaluation: Research Methods, Statistics & Stability Evidence
BUDs, concentrations, compatibility decisions and new services all rest on published evidence. The BCSCP outline lists literature evaluation as practice-management task 3B2, covering research methods, statistics and whether a study applies to your patients and preparations. For a compounding specialist, the most common literature is the stability or compatibility study , and USP <797> requires Category 3 BUDs to rest on stability-indicating evidence.
Levels of information
Level Examples How to use it
Tertiary Trissel's Handbook on Injectable Drugs, King Guide to Parenteral Admixtures, ASHP's Extended Stability for Parenteral Drugs, drug-information databases, Stabilis Quick screening; check the entry's cited primary study before assigning a BUD
Secondary PubMed, Embase, International Pharmaceutical Abstracts Find primary studies
Primary Stability and compatibility studies, clinical trials, cohort studies The actual evidence; judge its methods
USP also publishes a Stability Study Reference Document that explains when a stability study is suitable for assigning Category 3 BUDs.
Judging a stability study for BUD use
Checklist, with every answer needing to be yes:
Stability-indicating method. Is it HPLC or similar, shown by forced degradation (acid, base, oxidation, heat, light) to separate the drug from its degradants? A simple UV absorbance method may read degradants as intact drug.
Method validation. Were specificity, accuracy, precision, linearity and range shown, for example against USP <1225>?
Same formulation. Same drug (and salt form), concentration range, diluent, excipients and pH.
Same container materials. PVC, polyolefin, glass and syringe type all matter, because of sorption and leaching.
Same storage conditions. Temperature, light exposure, and any shift from frozen to refrigerated to room temperature.
Adequate time points and replicates. The time points must cover the BUD being assigned, with at least 3 replicates.
Physical stability too. pH, color, clarity, particulate matter and precipitation.
Acceptance criteria. Typically at least 90% of the initial concentration remaining, and no clinically significant degradants. Stricter criteria apply if a degradant is toxic.
Remember that stability studies usually say nothing about sterility . The BUD must also respect the USP <797> category limits and sterility testing requirements. For Category 3, USP's FAQ allows a published or unpublished study, but only when the formulation, procedure and container are exactly the same as the CSP's.
Worked kinetics: t90 for first-order degradation
For first-order degradation, ln C = ln C 0 − k t \ln C = \ln C_0 - kt ln C = ln C 0 − k t . The time until 90% remains is t 90 = ln ( 1 / 0.9 ) k = 0.105 k t_{90} = \frac{\ln(1/0.9)}{k} = \frac{0.105}{k} t 90 = k ln ( 1/0.9 ) = k 0.105
If a study reports k = 0.0035 day − 1 k = 0.0035\ \text{day}^{-1} k = 0.0035 day − 1 at 5 °C, then t 90 = 0.105 ÷ 0.0035 = 30 t_{90} = 0.105 \div 0.0035 = 30 t 90 = 0.105 ÷ 0.0035 = 30 days. Better studies estimate shelf life from the lower 95% confidence limit of the regression line, not just the mean, which gives a more conservative date.
Judging a compatibility study
Physical compatibility is judged visually (against a light and a dark background, and with a Tyndall beam), by turbidity measurement, and by particle counting. A lack of visible change does not rule out microprecipitates.
Chemical compatibility needs a stability-indicating assay of each drug in the mixture.
Results apply only to the concentrations, ratios, diluents and contact times tested. "Compatible at Y-site for 4 hours at 1 mg/mL" says nothing about 5 mg/mL or about 24 hours in the same bag.
Conflicting reports are common. Weigh the method quality, not just the number of studies.
Clinical study designs
Design Strength Example question in sterile therapy
Systematic review and meta-analysis Pools the best evidence Do CHG-alcohol dressings reduce CLABSI?
Randomized controlled trial Tests cause and effect; limits confounding Extended versus intermittent beta-lactam infusion
- Cohort study Follows exposure to outcome; good for harms Outcomes of home PN patients by catheter type
- Case-control study Efficient for rare outcomes Risk factors in a fungal outbreak
- Case series or report Signal detection New incompatibility or adverse event
Also check for bias (selection, performance, detection, attrition), confounding, blinding, sample size and power, and who funded the study.
Core statistics
Mean, standard deviation and coefficient of variation describe precision, for example the ACD accuracy spread.
Confidence interval (CI): a 95% CI for a difference that crosses 0 (or a ratio CI that crosses 1) means the result is not statistically significant.
p-value: the probability of results this extreme if there were truly no effect. p < 0.05 p < 0.05 p < 0.05 is conventional. Statistical significance is not the same as clinical importance.
Type I error is a false positive (alpha); type II error is a false negative (beta). Power is 1 − beta, usually targeted at 80% or more.
Relative versus absolute risk: if CLABSI falls from 4% to 2%, the relative risk reduction is 50%, but the absolute risk reduction (ARR) is 2 percentage points, and NNT = 1 ÷ 0.02 = 50 \text{NNT} = 1 \div 0.02 = 50 NNT = 1 ÷ 0.02 = 50 .
Sensitivity and specificity matter when judging tests, such as rapid microbiological methods for sterility.
Applicability: does this study fit my CSP and my patients?
Ask whether the population, setting, product, container and conditions match yours. Separate internal validity (was the study done well?) from external validity (does it apply here?). A well-done neonatal study in glass syringes does not automatically support an adult elastomeric pump BUD.